Home > Insider Trading > Filing (0001209191-18-003473)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704483	Robert Berman	C/O Biohaven Pharmaceuticals, Inc. 234 Church Street New Haven CT 06510	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2018-01-10	4,945	$27.09	606,055	No	4	S	Indirect	By Berman Family Trust 2013
Common Shares	Disposition	2018-01-10	1,575	$28.29	604,480	No	4	S	Indirect	By Berman Family Trust 2013
Common Shares	Disposition	2018-01-10	460	$29.37	604,020	No	4	S	Indirect	By Berman Family Trust 2013
Common Shares	Disposition	2018-01-10	20	$29.98	604,000	No	4	S	Indirect	By Berman Family Trust 2013
Common Shares	Disposition	2018-01-10	19,780	$27.09	474,220	No	4	S	Indirect	By Berman Marital Trust 2013
Common Shares	Disposition	2018-01-10	6,300	$28.29	467,920	No	4	S	Indirect	By Berman Marital Trust 2013
Common Shares	Disposition	2018-01-10	1,840	$29.37	466,080	No	4	S	Indirect	By Berman Marital Trust 2013
Common Shares	Disposition	2018-01-10	80	$29.98	466,000	No	4	S	Indirect	By Berman Marital Trust 2013

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Berman Family Trust 2013
No	4	S	Indirect	By Berman Family Trust 2013
No	4	S	Indirect	By Berman Family Trust 2013
No	4	S	Indirect	By Berman Family Trust 2013
No	4	S	Indirect	By Berman Marital Trust 2013
No	4	S	Indirect	By Berman Marital Trust 2013
No	4	S	Indirect	By Berman Marital Trust 2013
No	4	S	Indirect	By Berman Marital Trust 2013

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	50	Indirect	Owned by spouse

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 - $27.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.83 - $28.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 - $29.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.